Marinus Pharmaceuticals I...
0.54
0.00 (0.19%)
At close: Jan 15, 2025, 3:00 PM
undefined%
Bid 0.54
Market Cap 29.91M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.47
PE Ratio (ttm) -0.22
Forward PE n/a
Analyst Hold
Ask 0.54
Volume 1,032,380
Avg. Volume (20D) 3,515,034
Open 0.54
Previous Close 0.54
Day's Range 0.54 - 0.54
52-Week Range 0.22 - 10.50
Beta undefined

About MRNS

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2014
Employees 165
Stock Exchange NASDAQ
Ticker Symbol MRNS

Analyst Forecast

According to 12 analyst ratings, the average rating for MRNS stock is "Hold." The 12-month stock price forecast is $2.5, which is an increase of 361.60% from the latest price.

Buy 33.33%
Hold 58.33%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Marinus Pharmaceuticals Inc. is scheduled to release its earnings on Mar 4, 2025, during market hours.
Analysts project revenue of $10.59M, reflecting a 47.29% YoY growth and earnings per share of -0.35, making a -52.70% decrease YoY.
2 weeks ago · Source
+41.65%
Marinus Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
2 months ago · Source
-82.49%
Marinus Pharmaceuticals shares are trading lower after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.